1. Home
  2. BFRI

BFRI

Biofrontera Inc.

Logo Biofrontera Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 3:57pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Founded: 1997 Country:
United States
United States
Employees: N/A City: WOBURN
Market Cap: 8.7M IPO Year: 2021
Target Price: $18.00 AVG Volume (30 days): 800.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -13.02 EPS Growth: N/A
52 Week Low/High: $0.61 - $13.42 Next Earning Date: 05-10-2024
Revenue: $34,071,000 Revenue Growth: 18.82%
Revenue Growth (this year): 28.46% Revenue Growth (next year): 20.47%

Share on Social Networks: